ArticleArthritis research & therapy2008
Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis.
Article in Arthritis research & therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 141 citations in OpenAlex.
- Advancement of humanized mice and leading applications in immunological disease models.Inflammation and regeneration · 2026Review
- Dual action tofacitinib-loaded PLGA nanoparticles alleviate colitis in an IBD mouse model.Drug delivery and translational research · 2025Article
- Unveiling the Therapeutic Potential: Targeting Fibroblast-like Synoviocytes in Rheumatoid Arthritis.Expert reviews in molecular medicine · 2025Review
- Sequential JAK inhibition enhances antitumor immunity after combined anti-PD-1 and anti-CTLA4.JCI insight · 2025Article
- Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.Annals of the rheumatic diseases · 2024Review
- Clinical Scoring of Disease Activity in Animal Models.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Etiology and Pathogenesis of Rheumatoid Arthritis-Interstitial Lung Disease.International journal of molecular sciences · 2023Review
- Tofacitinib Suppresses Natural Killer CellsFrontiers in immunology · 2022Article
- Tofacitinib Inhibits STAT Phosphorylation and Matrix Metalloproteinase-3, -9 and -13 Production by C28/I2 Human Juvenile Chondrocytes.Open access rheumatology : research and reviews · 2022Article
- Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis.Arthritis research & therapy · 2021Article
- Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression.Molecular human reproduction · 2021Article
- Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis.Journal of inflammation research · 2021Article
- Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing.International journal of molecular sciences · 2020Article
- PreclinicalFrontiers in bioengineering and biotechnology · 2020Article
- Alterations of voluntary behavior in the course of disease progress and pharmacotherapy in mice with collagen-induced arthritis.Arthritis research & therapy · 2019Article
- Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats.The AAPS journal · 2019Article
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases.Frontiers in immunology · 2019Review
- Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis.Scientific reports · 2018Article
- Regulation of T-Cell Signaling by Post-Translational Modifications in Autoimmune Disease.International journal of molecular sciences · 2018Review
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Nature reviews. Drug discovery · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCP-690550 is a small molecule inhibitor of Janus kinase 3 (JAK3), a critical enzyme in the signaling pathway of multiple cytokines (interleukin (IL)-2, -7, -15 and -21) that are important in various T cell functions including development, activation and homeostasis. The purpose of this study was to evaluate CP-690550 in murine collagen-induced (CIA) and rat adjuvant-induced (AA) models of rheumatoid arthritis (RA).
methodsCIA and AA were induced using standard protocols and animals received the JAK3 inhibitor via osmotic mini-pump infusion at doses ranging from 1.5-15 mg/kg/day following disease induction. Arthritis was assessed by clinical scores in the CIA models and paw swelling monitored using a plethysmometer in the AA model until study conclusion, at which time animals were killed and evaluated histologically.
resultsCP-690550 dose-dependently decreased endpoints of disease in both RA models with greater than 90% reduction observed at the highest administered dose. An approximate ED50 of approximately 1.5 mg/kg/day was determined for the compound based upon disease endpoints in both RA models examined and corresponds to CP-690550 serum levels of 5.8 ng/ml in mice (day 28) and 24 ng/ml in rats (day 24). The compound also reduced inflammatory cell influx and joint damage as measured histologically. Animals receiving a CP-690550 dose of 15 mg/k/d showed no histological evidence of disease.
conclusionThe efficacy observed with CP-690550 in CIA and AA suggests JAK3 inhibition may represent a novel therapeutic target for the treatment of RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.